

CHANGE - ANNOUNCEMENT OF APPOINTMENT::APPOINTMENT OF ACTING DEPUTY CHIEF EXECUTIVE OFFICER

Issuer & Securities

Issuer/ Manager

ISEC HEALTHCARE LTD.

Securities

ISEC HEALTHCARE LTD. - SG1AD9000001 - 40T

Stapled Security

No

Announcement Details

Announcement Title

Change - Announcement of Appointment

Date & Time of Broadcast

28-Aug-2026 22:58:20

Status

New

Announcement Sub Title

APPOINTMENT OF ACTING DEPUTY CHIEF EXECUTIVE OFFICER

Announcement Reference

SG260828OTHRKAHM

Submitted By (Co./ Ind. Name)

Yoo Loo Ping

Designation

Company Secretary

Description (Please provide a detailed description of the event in the box below)

Appointment of Dr Shin Hoy Choong as Acting Deputy Chief Executive Officer.

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

Additional Details

Date of appointment

01/09/2026

Name of person

Shin Hoy Choong

Age

52

Country of principal residence

Malaysia

The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process)

The Board of Directors having reviewed and considered the qualifications of Dr Shin Hoy Choong ("Dr Shin") and upon recommendation of the Nominating Committee, is of the view that Dr Shin is suitable for the appointment of Acting Deputy Chief Executive Officer and has approved the appointment with effect from 1 September 2026 up to 26 May 2027, being the date of expiry of the current term of his contract of employment with IE Centre Sdn. Bhd. ("IE Centre"), unless his appointment to the role on a permanent basis is confirmed by the Board of Directors before such date.

Whether appointment is executive, and if so, the area of responsibility

Executive.

Dr Shin will work closely with the Chief Executive Officer to drive the strategic growth of ISEC's eyecare business, providing strategic vision, operational leadership and business development expertise, including identifying new opportunities, implementing expansion initiatives and ensuring alignment with ISEC's long-term objectives.

Job title (e.g. Lead ID, AC Chairman, AC Member etc.)

Acting Deputy Chief Executive Officer

Professional qualifications

Bachelor of Medicine and Bachelor of Surgery (University of Malaya) Malaysia

Master of Ophthalmology (University of Malaya) Malaysia

Working experience and occupation(s) during the past 10 years

2010 to 2022

Consultant Ophthalmologist/Founder

- IE Centre Sdn. Bhd.

2019 to 2022

Consultant Ophthalmologist/Founder

- Kampar Eye Sdn. Bhd.

2022 to Present

Medical Director

- ISEC Perak group of companies

Ipoh Centre Director

- ISEC Healthcare Ltd.

[Shareholding interest in the listed issuer and its subsidiaries](#)

Yes

[Shareholding details](#)

6,301,358 Ordinary Shares in the capital of the Company

[Any relationship \(including immediate family relationships\) with any existing director, existing executive officer, the issuer and/or substantial shareholder of the listed issuer or of any of its principal subsidiaries](#)

Dr Shin is one of the Vendors for the Group's acquisition of IE Centre and Kampar Eye Sdn. Bhd. ("Kampar Eye"), as well as a shareholder of ME Centre Sdn Bhd ("ME Centre"), TE Centre Sdn Bhd ("TE Centre"), Taiping Eye Sdn Bhd ("Taiping Eye").

The following agreements were entered into between ISEC Sdn. Bhd. and among others Dr Shin:

1. Share Purchase and Subscription Agreement dated 6 April 2022 ("SPSA") between ISEC Sdn. Bhd. and Dr Shin, Tan Hooi Ngea, Yong Ked Sheong, Cheng Heng Liang, Chan Suet Mei, Jane Foo Mei Li, ME Centre, TE Centre and Taiping Eye;
2. Shareholders' Agreements dated 26 May 2022 in relation to ME Centre and TE Centre; and
3. Shareholders' Agreement dated 26 May 2022 in relation to Taiping Eye.

Subsequent to completing the proposed subscription, Dr Shin remains as a shareholder in ME Centre, TE Centre and Taiping Eye.

Please refer to the Company's announcements dated 7 April 2022 and 26 May 2022 for details.

In addition, the Group has entered into the following agreements involving Dr Shin and/or his related parties:

1. Tenancy Agreement between IE Centre (tenant) and Tan Hooi Ngea (landlord), spouse of Dr Shin;
2. Tenancy Agreement between Kampar Eye (tenant) and IE Properties Sdn. Bhd. (landlord), a company of which Dr Shin and Tan Hooi Ngea are directors; and
3. Shareholder advances to TE Centre, ME Centre and Taiping Eye.

[Conflict of interest \(including any competing business\)](#)

No

[Undertaking \(in the format set out in Appendix 7.7 or Appendix 7H\) under Mainboard Rule 720\(1\) or Catalist Rule 720\(1\) has been submitted to the listed issuer](#)

Yes

[Other Principal Commitments* Including Directorships#](#)

* "Principal Commitments" has the same meaning as defined in the Code of Corporate Governance.

These fields are not applicable for announcements of appointments pursuant to Mainboard Rule 704(9) or Catalist Rule 704(8).

[Past \(for the last 5 years\)](#)

N.A.

[Present](#)

2010 to Present

Executive Director

- IE Centre Sdn. Bhd.

2017 to Present
Executive Director
- Kampar Eye Sdn. Bhd.

2020 to Present
Executive Director
- ME Centre Sdn. Bhd.

2020 to Present
Executive Director
- TE Centre Sdn. Bhd.

2021 to Present
Executive Director
-Taiping Eye Sdn. Bhd.

2016 to Present
Director
- IE Properties Sdn. Bhd.

2016 to Present
Director
- IE Best Agro Sdn. Bhd.

Information Required

Disclose the following matters concerning an appointment of director, chief executive officer, chief financial officer, chief operating officer, general manager or other officer of equivalent rank. If the answer to any question is "yes", full details must be given.

(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?

No

(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?

No

(c) Whether there is any unsatisfied judgment against him?

No

(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?

No

(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?

No

(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?

No

(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?

No

(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?

No

(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?

No

(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of:-

(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or

No

(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or

No

(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or

No

(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere,

in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?

No

(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?

No

Disclosure applicable to the appointment of director only.

Any prior experience as a director of an issuer listed on the Exchange?

No

If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange.

This relates to the appointment of an Executive Officer.
